Syldenafil i Terazosyna: interakcja

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives.

Hypotension when Co-administered with Alpha-blockers or Antihypertensives Alpha-blockers Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers.

Consider the following: Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor.

Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.

In patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose [see Dosage and Administration ( 2.2 ) ] .

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3).

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phosphodiesterase Type 5 Inhibitors (PDE5-I) Concomitant use of TEZRULY with other anti-hypertensive agents, especially the calcium channel blocker verapamil, can increase the risk of hypotension.

Hypotension has been reported when terazosin has been used with phosphodiesterase-5 (PDE-5) inhibitors.

Therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking TEZRULY.